Trial of VIS954 in the Treatment of Antineutrophil Cytoplasmic Antibody-associated Vasculitis

Study Identifier:
381-201-00020
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Study Contact Information:
Will Be Recruiting
Subscribe to Updates

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: VIS954
  • Drug: Standard Of Care (SOC)
  • Drug: Placebo
Date
Dec 2026 - Nov 2029
Phase 1/2
Phase 2/3
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information

Protocol Summary

This is a phase 2, double-blind, randomized, controlled, multicenter trial evaluating the efficacy, safety, pharmacokinetics, and pharmacodynamics of 2 VIS954 dosing regimens in patients with moderate to severe acute anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV).

Study Locations

No locations found.
© 2025 Otsuka America Pharmaceutical,
Inc All rights reserved.

July 2025 01US25EUC0279